Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology Surging
La EMA recomienda no aprobar el fármaco de Puma Biotech
Puma Pharma (@PumaPharma) / Twitter
PHARMA JONPI .: 08/24/14
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma – PHARMA
Puma – PHARMA
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener